1. Home
  2. NEON vs RNTX Comparison

NEON vs RNTX Comparison

Compare NEON & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neonode Inc.

NEON

Neonode Inc.

HOLD

Current Price

$1.65

Market Cap

27.9M

Sector

Technology

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.46

Market Cap

30.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEON
RNTX
Founded
1997
2001
Country
Sweden
United States
Employees
43
11
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.9M
30.0M
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
NEON
RNTX
Price
$1.65
$1.46
Analyst Decision
Hold
Buy
Analyst Count
1
2
Target Price
$6.00
$10.00
AVG Volume (30 Days)
96.7K
82.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
37.88
N/A
EPS
N/A
N/A
Revenue
$3,108,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$43.34
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.50
$1.02
52 Week High
$29.90
$2.22

Technical Indicators

Market Signals
Indicator
NEON
RNTX
Relative Strength Index (RSI) 44.20 67.89
Support Level N/A $1.34
Resistance Level $2.04 $1.57
Average True Range (ATR) 0.09 0.11
MACD -0.00 0.03
Stochastic Oscillator 34.44 86.82

Price Performance

Historical Comparison
NEON
RNTX

About NEON Neonode Inc.

Neonode Inc provides optical sensing solutions for contactless touch, and gesture sensing and also provides software solutions for machine perception that feature machine learning algorithms to detect and track persons and objects in video streams from cameras and other types of imagers. It markets and sells its solutions to customers in many different markets and segments including, office equipment, automotive, industrial automation, medical, military, and avionics. The company geographically operates in the United States, Japan, South Korea, Germany, Sweden, China, and other regions. A majority of its revenue is generated from Japan.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: